Xphozah is a phosphate absorption inhibitor that is used to lower serum phosphorus levels for patients with chronic kidney disease (CKD) on dialysis who have tried phosphate binders but they have worked well enough, or they are unable to take them.  Xphozah is a twice a daily tablet that works by blocking phosphate absorption in the gut to help return phosphate to normal serum levels. Xphozah is the first and only phosphate absorption inhibitor that has been approved by the Food and Drug Administration (FDA).

Xphozah (tenapanor) became an FDA-approved medication on Oct. 17, 2023, after positive results from three Phase 3 clinical trials (PHREEDOM, BLOCK, and AMPLIFY) showing Xphozah significantly reduced high serum phosphorus in patients receiving maintenance hemodialysis. Xphozah is FDA-approved to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or are intolerant of any dose of phosphate binder therapy.

Results from the three clinical trials showed that Xphozah significantly reduced elevated serum phosphorus in patients who were on maintenance hemodialysis.

What is hyperphosphatemia?

Hyperphosphatemia is when you have high or too much phosphorus in your blood. One of the kidneys' jobs is to filter out and remove excess phosphorus, but if you have kidney disease, your kidneys may not remove extra phosphorus, which leads to high phosphorus levels. High serum phosphorus levels are a common condition among people with chronic kidney disease (CKD) on maintenance dialysis. Treatment for high serum phosphorus levels is often with dietary restriction and phosphate binder therapy, but for those who do not get an adequate response or who are intolerant of phosphate binder therapy, Xphozah can be used as an add-on therapy or stand-alone therapy. Phosphate binders act by binding dietary phosphate to form insoluble complexes that pass through the GI tract without being absorbed.

Diarrhea. Patients using Xphozah may experience severe diarrhea. Treatment with this medicine should be discontinued in patients who develop severe diarrhea.

Usual adult Xphozah dose is a single tablet taken twice daily.

Xphozah is available as 10mg, 20mg, and 30mg tablets.

If a dose is missed, skip the missed dose and take the next dose at the regular time. Do not take 2 doses at the same time.

Xphozah is indicated for adult use.

You should not take Xphozah if:

• you have known or suspected mechanical gastrointestinal obstruction